Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Global Market Report 2025

The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market size has grown exponentially in recent years. It will grow from $1.31 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 23.5%. The growth during the historic period can be attributed to the rising prevalence of chronic respiratory diseases, increasing ICU admissions, the urgent need for optimized patient-specific ventilation strategies, growing demand for better patient outcomes, and expanding adoption of telemedicine and remote monitoring.

The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market size is expected to see exponential growth in the next few years. It will grow to $3.71 billion in 2029 at a compound annual growth rate (CAGR) of 23.2%. The growth during the forecast period can be attributed to the rising demand for personalized and efficient patient care, increasing investments in healthcare infrastructure, a growing geriatric population with respiratory conditions, rising healthcare costs driving efficiency solutions, and the need for continuous patient monitoring. Key trends in the forecast period include the integration of AI in critical care, advancements in machine learning algorithms, development of AI-based decision support systems, real-time monitoring and predictive analytics, and the creation of hybrid AI models that combine reinforcement learning with clinical data.

The rising prevalence of respiratory diseases is expected to drive the growth of the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market in the coming years. Respiratory diseases are conditions that affect the lungs and airways, impairing normal breathing and oxygen exchange. Their prevalence is increasing due to aging populations in developed nations, as older adults are more susceptible to chronic respiratory conditions because of weakened immune systems and cumulative environmental exposures. AI-enhanced ICU ventilation weaning supports the management of respiratory diseases by continuously analyzing patient-specific data, predicting optimal weaning times, reducing the duration of mechanical ventilation, minimizing complications, and enabling personalized, timely clinical interventions that improve patient outcomes. For example, in June 2024, according to the Australian Institute of Health and Welfare, in 2023 chronic obstructive pulmonary disease accounted for 3.6 percent of Australia’s total disease burden and represented half of the overall burden from respiratory conditions. Therefore, the rising prevalence of respiratory diseases is fueling the growth of the AI-enhanced ICU ventilation weaning market.

The growing emphasis on personalized medicine is expected to propel the growth of the AI-enhanced ICU ventilation weaning market in the coming years. Personalized medicine is an approach that tailors treatment and healthcare decisions to individual patients based on their genetic profile, lifestyle, and environmental factors. Its adoption is increasing due to advances in genomic technologies and data analytics, which enable more precise and individualized care across critical healthcare settings. AI-enhanced ventilation weaning systems support personalized medicine by analyzing individual patient data to determine optimal timing for mechanical ventilation removal, improving patient outcomes through customized treatment protocols. For instance, in February 2024, according to the Personalized Medicine Coalition, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from six in 2022, reflecting a rise of ten new approvals. Therefore, the growing focus on personalized medicine is driving the growth of the AI-enhanced ICU ventilation weaning market.

In October 2025, Etiometry Inc., a US-based software company specializing in AI-enhanced solutions for ventilator weaning in the ICU, partnered with Hospinorm FZCO to introduce its AI-driven platform in the UAE. Through this partnership, Hospinorm and Etiometry aim to bring FDA-cleared clinical decision-support technology to the region, providing clinicians with real-time insights, improving patient outcomes, and elevating critical care standards. The platform enables early detection of patient deterioration, standardizes care protocols, and optimizes resource utilization in intensive care units. Hospinorm FZCO is a UAE-based healthcare technology company focused on providing advanced medical solutions and innovative healthcare technologies.

Major players in the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market are Medtronic plc, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Nihon Kohden Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Hicuity Health Inc., Hospinorm Healthcare Pvt. Ltd., Clinomic (Mona) Ltd., Piramidal Technologies Ltd., Deep Breath Ltd., AgVa Healthcare Pvt. Ltd., Etiometry Inc., Clew Medical Ltd., AiiNTENSE Inc., Ambient Clinical Analytics Inc., Aerobiosys Innovations Pvt. Ltd., Caliber Interconnect Solutions Inc.

North America was the largest region in the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market research report is one of a series of new reports that provides artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market statistics, including artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning industry global market size, regional shares, competitors with the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market share, artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market segments, market trends, and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning industry. This artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning refers to the use of AI-driven algorithms to support the gradual reduction and eventual discontinuation of mechanical ventilation in critically ill patients. It utilizes real-time patient data to predict readiness for weaning, optimize ventilator settings, and minimize complications. This approach aims to improve patient outcomes, shorten the duration of ventilation, and reduce ICU-related risks.

The primary components of AI-enhanced ICU ventilation weaning include software, hardware, and services. Software consists of programs and algorithms that enable computers to perform tasks, analyze data, and provide actionable insights. These solutions can be deployed on-premises or via the cloud and are applied in adult, pediatric, and neonatal intensive care units. They serve a range of end-users, including hospitals, specialty clinics, and ambulatory surgical centers.

The countries covered in the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market consists of revenues earned by entities by providing services such as clinician decision support systems, remote monitoring and tele-ICU services, predictive analytics and risk assessment, workflow optimization solutions, training and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market also includes sales of ventilator monitoring systems, telerobotic ventilator controllers, and wearable respiratory sensors, and non-invasive ventilation (NIV) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.